Walleye Capital LLC Acquires Shares of 220,814 Protara Therapeutics, Inc. (NASDAQ:TARA)

Walleye Capital LLC purchased a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 220,814 shares of the company's stock, valued at approximately $1,166,000. Walleye Capital LLC owned 1.07% of Protara Therapeutics as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TARA. Geode Capital Management LLC boosted its position in Protara Therapeutics by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after buying an additional 9,553 shares during the period. Commonwealth Equity Services LLC boosted its position in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after acquiring an additional 17,572 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in shares of Protara Therapeutics by 12.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after purchasing an additional 22,301 shares during the period. Bailard Inc. purchased a new position in Protara Therapeutics during the 4th quarter valued at about $157,000. Finally, XTX Topco Ltd bought a new position in shares of Protara Therapeutics in the third quarter worth approximately $60,000. Institutional investors own 38.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on TARA shares. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Thursday, March 6th. Lifesci Capital assumed coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Scotiabank initiated coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 target price for the company. Finally, Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They set an "overweight" rating for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $20.40.

Insider Transactions at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the sale, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.50% of the company's stock.

Protara Therapeutics Stock Up 2.9 %

TARA traded up $0.12 during midday trading on Friday, reaching $4.23. The company had a trading volume of 141,900 shares, compared to its average volume of 769,719. Protara Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $10.48. The company has a market cap of $155.52 million, a P/E ratio of -1.50 and a beta of 1.60. The business has a 50-day moving average of $4.03 and a two-hundred day moving average of $3.96.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09. On average, equities research analysts predict that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.